Literature DB >> 33655949

Treatment of exostosin 1-associated membranous lupus nephritis with multiple low doses of rituximab: A case report.

Ling Li1, Zhi Yang1, Tian Tao1, Mei Yang2, Zhang-Xue Hu1.   

Abstract

RATIONALE: Membranous glomerulonephritis (MN) is the leading cause of nephrotic syndrome in adults and is classified as primary or secondary. Secondary MN accounts for 20% to 30% of all MN cases and can arise from a number of conditions, including autoimmune diseases. Recently exostosin 1/exostosin 2 (EXT1/EXT2) have been identified as the common antigens in secondary autoimmune MN and are present in cases of pure membranous lupus nephritis (LN). The treatment of EXT1/EXT2-associated MN remains elusive. PATIENT CONCERNS: We present the case of a 15-year-old female who presented with nephrotic syndrome, positive ANA and dsDNA, and low serum complements. A renal biopsy revealed pure membranous nephritis with IgG and C3 deposition. EXT1 was found along the glomerular capillary walls and stained positive, while phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) were negative. DIAGNOSIS: The patient was diagnosed with ETX1-associated membranous LN.
INTERVENTIONS: She was treated with prednisone and multiple low-dose rituximab (4 200 mg doses, approximately every 2 months, based on CD19+ cells counts). OUTCOMES: The patient had complete remission within 8 months later, and she remained in remission for the 16-month period of follow-up. LESSONS: To our knowledge, this is the first case of EXT1-associated MN that has been successfully treated by multiple low-dose rituximab. Further studies can investigate the optimal dosage and treatment protocol.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33655949      PMCID: PMC7939150          DOI: 10.1097/MD.0000000000024887

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  15 in total

1.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Authors:  Nicola M Tomas; Laurence H Beck; Catherine Meyer-Schwesinger; Barbara Seitz-Polski; Hong Ma; Gunther Zahner; Guillaume Dolla; Elion Hoxha; Udo Helmchen; Anne-Sophie Dabert-Gay; Delphine Debayle; Michael Merchant; Jon Klein; David J Salant; Rolf A K Stahl; Gérard Lambeau
Journal:  N Engl J Med       Date:  2014-11-13       Impact factor: 91.245

2.  Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.

Authors:  Roberta Fenoglio; Simone Baldovino; Savino Sciascia; Emanuele De Simone; Giulio Del Vecchio; Michela Ferro; Giacomo Quattrocchio; Carla Naretto; Dario Roccatello
Journal:  J Nephrol       Date:  2020-06-27       Impact factor: 3.902

Review 3.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

4.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Authors:  Fernando C Fervenza; Gerald B Appel; Sean J Barbour; Brad H Rovin; Richard A Lafayette; Nabeel Aslam; Jonathan A Jefferson; Patrick E Gipson; Dana V Rizk; John R Sedor; James F Simon; Ellen T McCarthy; Paul Brenchley; Sanjeev Sethi; Carmen Avila-Casado; Heather Beanlands; John C Lieske; David Philibert; Tingting Li; Lesley F Thomas; Dolly F Green; Luis A Juncos; Lada Beara-Lasic; Samuel S Blumenthal; Amy N Sussman; Stephen B Erickson; Michelle Hladunewich; Pietro A Canetta; Lee A Hebert; Nelson Leung; Jay Radhakrishnan; Heather N Reich; Samir V Parikh; Debbie S Gipson; Dominic K Lee; Bruno R da Costa; Peter Jüni; Daniel C Cattran
Journal:  N Engl J Med       Date:  2019-07-04       Impact factor: 91.245

Review 5.  The exostosin family: proteins with many functions.

Authors:  Marta Busse-Wicher; Krzysztof B Wicher; Marion Kusche-Gullberg
Journal:  Matrix Biol       Date:  2013-10-12       Impact factor: 11.583

6.  Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.

Authors:  Sanjeev Sethi; Benjamin J Madden; Hanna Debiec; M Cristine Charlesworth; LouAnn Gross; Aishwarya Ravindran; Amber M Hummel; Ulrich Specks; Fernando C Fervenza; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2019-05-06       Impact factor: 10.121

7.  Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1).

Authors:  J Ahn; H J Lüdecke; S Lindow; W A Horton; B Lee; M J Wagner; B Horsthemke; D E Wells
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

8.  Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center.

Authors:  K Neumann; D J Wallace; C Azen; S Nessim; M Fichman; A L Metzger; J R Klinenberg
Journal:  Semin Arthritis Rheum       Date:  1995-08       Impact factor: 5.532

9.  Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.

Authors:  Nathalie Chavarot; David Verhelst; Agathe Pardon; Valérie Caudwell; Lucile Mercadal; Antoinette Sacchi; Catherine Leonardi; Véronique Le Guern; Alexandre Karras; Eric Daugas
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

10.  Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report.

Authors:  Xiao-Pei Wang; Zhang-Xue Hu; Dong-Yang Guo; Ye Tao
Journal:  Chin Med J (Engl)       Date:  2016-04-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.